PMID- 21752873
OWN - NLM
STAT- MEDLINE
DCOM- 20111110
LR  - 20220311
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 50
IP  - 10
DP  - 2011 Oct
TI  - Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid 
      arthritis patients--REACTION 52-week study.
PG  - 1908-15
LID - 10.1093/rheumatology/ker221 [doi]
AB  - OBJECTIVES: To evaluate the effectiveness and safety of tocilizumab in RA 
      patients in clinical practice. METHODS: We observed 232 consecutive RA patients 
      who began tocilizumab in three rheumatology centres in Japan for 52 weeks. 
      Clinical, radiographic and functional status and safety were evaluated. RESULTS: 
      Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 
      years and average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8% 
      of the patients had been treated previously with anti-TNF biologics, clinical 
      remission at Week 52 was achieved in 43.7%, radiographic non-progression in 62.8% 
      and functional remission in 26.4%. Retention rate at Week 52 was 71.1%, and the 
      same for those with or without previous anti-TNF treatment. Adverse drug 
      reactions leading to tocilizumab discontinuation were observed in 15.5% of 
      patients, the most frequent adverse drug reaction being pneumonia in eight cases. 
      On multivariate logistic regression analysis, DAS-28, HAQ-disability index 
      (HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive 
      variables for clinical remission at Week 52 of tocilizumab treatment. In 
      particular, HAQ-DI was found to be a predictive variable for remission of all 
      three types-clinical, radiographic and functional-at Week 52 of tocilizumab 
      treatment. CONCLUSIONS: In daily clinical practice, tocilizumab exhibited 
      excellent effectiveness in established RA patients, some of whom had failed to 
      respond to previous anti-TNF treatment. Although further detailed safety findings 
      are required, this study provides valuable real-world findings on the management 
      of RA with tocilizumab.
FAU - Takeuchi, Tsutomu
AU  - Takeuchi T
AD  - Department of Internal Medicine, Division of Rheumatology, School of Medicine, 
      Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. 
      tsutake@z5.keio.jp
FAU - Tanaka, Yoshiya
AU  - Tanaka Y
FAU - Amano, Koichi
AU  - Amano K
FAU - Hoshi, Daisuke
AU  - Hoshi D
FAU - Nawata, Masao
AU  - Nawata M
FAU - Nagasawa, Hayato
AU  - Nagasawa H
FAU - Sato, Eri
AU  - Sato E
FAU - Saito, Kazuyoshi
AU  - Saito K
FAU - Kaneko, Yuko
AU  - Kaneko Y
FAU - Fukuyo, Shunsuke
AU  - Fukuyo S
FAU - Kurasawa, Takahiko
AU  - Kurasawa T
FAU - Hanami, Kentaro
AU  - Hanami K
FAU - Kameda, Hideto
AU  - Kameda H
FAU - Yamanaka, Hisashi
AU  - Yamanaka H
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110713
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Glucocorticoids)
RN  - I031V2H011 (tocilizumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnostic imaging/*drug therapy/physiopathology
MH  - Arthrography
MH  - Disability Evaluation
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Health Status
MH  - Humans
MH  - Joints/physiopathology
MH  - Male
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Recovery of Function
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
PMC - PMC3176715
EDAT- 2011/07/15 06:00
MHDA- 2011/11/11 06:00
PMCR- 2011/07/13
CRDT- 2011/07/15 06:00
PHST- 2011/07/15 06:00 [entrez]
PHST- 2011/07/15 06:00 [pubmed]
PHST- 2011/11/11 06:00 [medline]
PHST- 2011/07/13 00:00 [pmc-release]
AID - ker221 [pii]
AID - 10.1093/rheumatology/ker221 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2011 Oct;50(10):1908-15. doi: 10.1093/rheumatology/ker221. 
      Epub 2011 Jul 13.